Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 563-573

  Baehner, Frederick L ^a,b   Lee, Mark ^b   Demeure, Michael J ^c,d   Bussey, Kimberly J ^c   Kiefer, Jeffrey A ^c   Barrett, Michael T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Genomic Health Inc   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d HonorHealth Research Institute   (United States)

Author keywords

adrenal cancer; biomarkers; breast cancer; colon cancer; gene expression array

Indexed keywords

ANASTROZOLE; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DIMETHYLENASTRON; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; METHOTREXATE; MITOTANE; MONASTROL; S TRITYLCYSTEINE; SOMATOMEDIN B; TAMOXIFEN; TRANSCRIPTOME; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; DRUG EFFICACY; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VALIDATION STUDY;

ADRENAL CORTEX NEOPLASMS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK ASSESSMENT;

EID: 79953845002     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21838     Document Type: Article

References (53)

1. Fisher B, Jeong JH, Bryant J, et al.: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-868.
2. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
3. Viale G, Regan MM, Mastropasqua MG, et al.: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212. (Pubitemid 351480546)
4. Dowsett M, Goldhirsch A, Hayes DF, et al.: International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007; 9: R81.
5. Moore G,: Cramming more components onto integrated circuits. Electronics 1965; 38.
6. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
7. van de Vijver MJ, He YD, van't Veer LJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
8. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
9. Cobleigh MA, Tabesh B, Bitterman P, et al.: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005; 11: 8623-8631. (Pubitemid 43005909)
10. Mina L, Soule SE, Badve S, et al.: Predicting response to primary chemotherapy: Gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007; 103: 197-208. (Pubitemid 46789142)
11. Cronin M, Pho M, Dutta D, et al.: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004; 164: 35-42. (Pubitemid 38364587)
12. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
13. Fox MS,: On the diagnosis and treatment of breast cancer. JAMA 1979; 241: 489-494. (Pubitemid 9228143)
14. van 't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. (Pubitemid 34130608)
15. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734. (Pubitemid 46622311)
16. Simon R,: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005; 97: 866-867. (Pubitemid 41417930)
17. Perou CM, Jeffrey SS, van de Rijn M, et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-9217. (Pubitemid 29374734)
18. Parker JS, Mullins M, Cheang MC, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
19. Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
20. Paik S, Shak S, Tang G, et al.: Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. In: ASCO Annual Meeting, Atlanta, GA, 2005.
21. Goldstein LJ, Gray R, Badve S, et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-4071.
22. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
23. Dowsett M, Cuzick J, Wale C, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010; 28: 1829-1834.
24. Badve S, Gray R, Childs B, et al.: ER and PR assessment by central IHC: examination and comparison of percent positive cells and nuclear staining intensity in ECOG Breast Cancer Study 2197. In: United States and Canadian Academy of Pathology, Boston, MA, 2009.
25. Baehner FL, Achacoso N, Maddala T, et al.: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010; 28: 4300-4306.
26. Baehner F, Hiller B, Kim C, et al.: Use of macro dissection in multi-gene RNA analysis of fixed paraffin-embedded tumor tissue. In: United States and Canada Academy of Pathology Vancouver, British Columbia, Canada, 2004.
27. Baehner F, Baker J, Salter M, et al.: Heterogeneity of quantitative RT-PCR measurement of estrogen and progresterone receptor expression: Comparison of tissue microarray cores to whole sections of paraffin embedded breast cancer tissue. In: United States and Canada Academy of Pathology, Denver, CO, 2008.
28. Vicuna B, Benson AB III:, Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers. J Natl Compr Canc Netw 2007; 5: 927-936. (Pubitemid 350069531)
29. National Comprehensive Cancer Network Practice, Guidelines in Oncology. Colon Cancer. 2010.
30. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206. (Pubitemid 32319494)
31. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257. (Pubitemid 36859476)
32. Popat S, Hubner R, Houlston RS,: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618. (Pubitemid 46224239)
33. Roth A, Tejpar S, Yan P, et al.: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK60-0 trial. J Clin Oncol (suppl) 2009; (abstract 4002 and page 1695).
34. Sargent DJ, Marsoni S, Monges G, et al.: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
35. Clark-Langone KM, Wu JY, Sangli C, et al.: Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007; 8: 279.
36. O'Connell MJ, Lavery I, Yothers G, et al.: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28: 3937-3944.
37. Gray R, Barnwell J, McConkey C, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020-2029.
38. Kerr D, Gray R, Quirke P, et al.: A quantitative mutligene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol (Suppl) 2009; (abstract 4000 and page 1695).
39. Berruti A, Terzolo M, Sperone P, et al.: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657-666. (Pubitemid 41482999)
40. Maley CC, Galipeau PC, Finley JC, et al.: Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-473.
41. Merlo LM, Pepper JW, Reid BJ, et al.: Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-935. (Pubitemid 44862677)
42. Weir BA, Woo MS, Getz G, et al.: Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898. (Pubitemid 350231325)
43. Wood LD, Parsons DW, Jones S, et al.: The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113. (Pubitemid 350134889)
44. Thomas RK, Baker AC, Debiasi RM, et al.: High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351. (Pubitemid 46328493)
45. Fottner C, Hoeflich A, Wolf E, et al.: Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 2004; 36: 397-405. (Pubitemid 38932097)
46. Villa R, Orlandi L, Berruti A, et al.: Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999; 14: 133-138.
47. Stephan EA, Chung TH, Grant CS, et al.: Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 2008; 7: 425-431. (Pubitemid 351302536)
48. Barrett MT, Scheffer A, Ben-Dor A, et al.: Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 2004; 101: 17765-17770. (Pubitemid 40051961)
49. de Smith AJ, Tsalenko A, Sampas N, et al.: Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: Implications for association studies of complex diseases. Hum Mol Genet 2007; 16: 2783-2794. (Pubitemid 350048378)
50. Wolf M, Mousses S, Hautaniemi S, et al.: High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: Impact of copy number on gene expression. Neoplasia 2004; 6: 240-247. (Pubitemid 38657080)
51. Lipson D, Aumann Y, Ben-Dor A, et al.: Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol 2006; 13: 215-228.
52. Crowder RJ, Enomoto H, Yang M, et al.: Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J Biol Chem 2004; 279: 42072-42081. (Pubitemid 39328148)
53. Lai AZ, Gujral TS, Mulligan LM,: RET signaling in endocrine tumors: Delving deeper into molecular mechanisms. Endocr Pathol 2007; 18: 57-67. (Pubitemid 47574988)